In primary OA chondrocytes, IL‐1β + MF63 compared with IL‐1β alone yielded gene expression FC 3.68 for MT1B and FC 2.15 for IL36RN. In BMDMs, MTT assessment showed no difference in viability between the drug groups (MF63, MK886) and the control group. In BHK cells, MF63 triggered F508del-CFTR trafficking to the same level as glafenine. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
MF63 and MT1B Expression in OA Chondrocytes
Cell-based study · primary OA chondrocytes; n = 10 [1]
Primary OA chondrocytes were treated with IL‐1β + MF63 for 24 h and compared with IL‐1β alone. MT1B gene expression showed FC 3.68, with FDR‐adjusted P‐value <0.0001.
Literature-Reported Treatment Conditions
- Exposure duration
- 24 h
- Co-treatment
- Other interventions in this design: IL‐1β. Compound effect isolated by the comparison: IL‐1β + MF63; IL‐1β.
- Reported limits
- Not stated in the sentences used: dose, route, vehicle. Removed after verification: value.
Methods and source locations
Compound reported in the paper: MF63
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
METHODS > Next‐generation sequencing and data analysis (S11, S13); TABLE 4 legend (S83); TABLE 4 (T4.h1, T4.r1)
MT1B; Gene expression levels: MT1B; Gene expression levels; comparator: IL‐1β — TABLE 4 legend (S83); TABLE 4 (T4.h1, T4.r1)
MF63 and BMDM Viability
Cell-based study · BMDM (10⁴ cells per well) [2]
BMDM viability following MF63 treatment was assessed using the MTT assay. No difference was observed between the drug groups (MF63, MK886) and the control group.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 × 10−9 M
- Method
- Following treatment with MF63
- Co-treatment
- Other interventions in this design: macrophage colony-stimulating factor 20 ng/mL; lipopolysaccharide 1 μg/mL. Compound effect isolated by the comparison: between the drug groups (MF63, MK886) and the control group.
- Reported limits
- Not stated in the sentences used: schedule, vehicle.
Methods and source locations
Compound reported in the paper: MF63
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Culture of bovine BMDMs (S10, S11); Materials and methods > Cell viability assay (S17, S18); Results > Selection of drug concentrations of mPGES-1 inhibitors in Escherichia coli infected BMDM (S41); Figure 1 legend (S80)
Cell viability of MF63 (1 × 10−9 M)-treated BMDMs was assessed using the MTT assay: Cell viability of MF63 (1 × 10−9 M)-treated BMDMs was assessed using the MTT assay; comparator: control group — Results > Selection of drug concentrations of mPGES-1 inhibitors in Escherichia coli infected BMDM (S41); Figure 1 legend (S80)
MF63 and F508del-CFTR Trafficking in BHK Cells
Cell-based study · BHK cells [3]
BHK cells were treated with MF63 at 10 μM for 24 h. MF63 triggered F508del-CFTR trafficking to the same level as glafenine.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- 24 h
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: MF63
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Glafenine corrects F508del-CFTR via the arachidonic acid pathway (S92); Materials and methods > High throughput screening assay (S155, S156); Figure 5 legend (S256)
surface F508del-CFTR: surface F508del-CFTR; comparator: untreated control cells — Results > Glafenine corrects F508del-CFTR via the arachidonic acid pathway (S92); Figure 5 legend (S256)
MF63 and IL36RN Expression in OA Chondrocytes
Cell-based study · primary OA chondrocytes; n = 10 [1]
Primary OA chondrocytes were treated with IL‐1β + MF63 for 24 h and compared with IL‐1β alone. IL36RN gene expression showed FC 2.15, with FDR‐adjusted P‐value <0.0001.
Literature-Reported Treatment Conditions
- Exposure duration
- 24 h
- Co-treatment
- Other interventions in this design: IL‐1β. Compound effect isolated by the comparison: IL‐1β + MF63; IL‐1β.
- Reported limits
- Not stated in the sentences used: dose, route, vehicle. Removed after verification: value.
Methods and source locations
Compound reported in the paper: MF63
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
METHODS > Next‐generation sequencing and data analysis (S11, S13); TABLE 4 legend (S83); TABLE 4 (T4.h1, T4.r15)
IL36RN; Gene expression levels: IL36RN; Gene expression levels; comparator: IL‐1β — TABLE 4 legend (S83); TABLE 4 (T4.h1, T4.r15)